Early Low-Molecular-Weight Heparin Thromboprophylaxis and Venous Thromboembolism During Neoadjuvant Chemotherapy for Advanced Ovarian Cancer

Background/Objectives: Venous thromboembolism is common during neoadjuvant chemotherapy for advanced ovarian cancer, but when to start thromboprophylaxis is unclear. We evaluated the association between early prophylactic-dose low-molecular-weight heparin, started at diagnosis or before the first cycle, and venous thromboembolism during neoadjuvant chemotherapy. Methods: This retrospective single-center cohort study included all consecutive women with stage III–IV epithelial ovarian cancer diagnosed between September 2012 and January 2025 who received neoadjuvant chemotherapy. Patients with venous thromboembolism at diagnosis were excluded. The primary endpoint was confirmed venous thromboembolism from the first cycle until interval debulking surgery or, without surgery, until completion of planned neoadjuvant chemotherapy or day 120, whichever occurred first. Associations were explored with Firth-penalized logistic regression. Results: Of 201 patients who received neoadjuvant chemotherapy, 192 formed the analytic cohort; 148 (77.1%) received early prophylaxis. Primary endpoint events occurred in 7 patients (3.6%; six pulmonary embolisms) at a median of 3.1 weeks after diagnosis. Events occurred in 1 of 148 patients (0.7%) with early prophylaxis and 6 of 44 (13.6%) without it. In exploratory multivariable analysis, early prophylaxis remained associated with lower odds (adjusted odds ratio [OR] 0.08, 95% confidence interval [CI] 0.01–0.47). A Khorana score of 3 or higher was associated with higher, imprecisely estimated odds (adjusted OR 12.70, 95% CI 1.17–1722). No major or clinically relevant non-major bleeding was identified (0/148 with prophylaxis; 95% CI 0–2.46%). Conclusions: Early prophylactic-dose low-molecular-weight heparin was associated with fewer venous thromboembolic events during neoadjuvant chemotherapy. Because prophylaxis was not randomized and events were few, these hypothesis-generating findings require prospective validation.

Authors

Institutions

Publication Details

Journal
Cancers
Published
2026-11-19
DOI
https://doi.org/10.3390/cancers18223702
Primary Topic
Venous Thromboembolism Diagnosis and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Early Low-Molecular-Weight Heparin Thromboprophylaxis and Venous Thromboembolism During Neoadjuvant Chemotherapy for Advanced Ovarian Cancer

Hasan Volkan Ege, Murat Gültekin, Zafer Selçuk Tuncer, Derman Başaran et al.
Cancers
Venous Thromboembolism Diagnosis and Management
article

Early Low-Molecular-Weight Heparin Thromboprophylaxis and Venous Thromboembolism During Neoadjuvant Chemotherapy for Advanced Ovarian Cancer

Hasan Volkan Ege, Murat Gültekin, Zafer Selçuk Tuncer, Derman Başaran, Haticegül Tuncer, Semih Ergişi
article en

Abstract

Background/Objectives: Venous thromboembolism is common during neoadjuvant chemotherapy for advanced ovarian cancer, but when to start thromboprophylaxis is unclear. We evaluated the association between early prophylactic-dose low-molecular-weight heparin, started at diagnosis or before the first cycle, and venous thromboembolism during neoadjuvant chemotherapy. Methods: This retrospective single-center cohort study included all consecutive women with stage III–IV epithelial ovarian cancer diagnosed between September 2012 and January 2025 who received neoadjuvant chemotherapy. Patients with venous thromboembolism at diagnosis were excluded. The primary endpoint was confirmed venous thromboembolism from the first cycle until interval debulking surgery or, without surgery, until completion of planned neoadjuvant chemotherapy or day 120, whichever occurred first. Associations were explored with Firth-penalized logistic regression. Results: Of 201 patients who received neoadjuvant chemotherapy, 192 formed the analytic cohort; 148 (77.1%) received early prophylaxis. Primary endpoint events occurred in 7 patients (3.6%; six pulmonary embolisms) at a median of 3.1 weeks after diagnosis. Events occurred in 1 of 148 patients (0.7%) with early prophylaxis and 6 of 44 (13.6%) without it. In exploratory multivariable analysis, early prophylaxis remained associated with lower odds (adjusted odds ratio [OR] 0.08, 95% confidence interval [CI] 0.01–0.47). A Khorana score of 3 or higher was associated with higher, imprecisely estimated odds (adjusted OR 12.70, 95% CI 1.17–1722). No major or clinically relevant non-major bleeding was identified (0/148 with prophylaxis; 95% CI 0–2.46%). Conclusions: Early prophylactic-dose low-molecular-weight heparin was associated with fewer venous thromboembolic events during neoadjuvant chemotherapy. Because prophylaxis was not randomized and events were few, these hypothesis-generating findings require prospective validation.

CancersVol. 18(22)
Memorial Ankara Hospital (TR), Hacettepe University (TR)
Venous Thromboembolism Diagnosis and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon